TSPYL2 reduced gefitinib resistance and DNA damage repair via suppressing SIRT1-mediated FOXO3 deacetylation.
In: Future medicinal chemistry, Jg. 14 (2022-03-01), Heft 6, S. 407-419
academicJournal
Zugriff:
Background: Colorectal cancer (CRC) is a malignancy with high mortality. TSPYL2 participates in tumor suppression but its role in CRC remains unknown. Methodology & results: TSPYL2 was downregulated and SIRT1 was upregulated in gefitinib drug-resistant (GEF-DR) tissues of patients with CRC. The GEF-resistant cells, HCT116 and HCT-15, were successfully established. The knockdown of TSPYL2 promoted resistance to GEF in CRC cells. Interestingly, immunofluorescence and western blot assays demonstrated that TSPYL2 inhibited DNA damage repair in HCT-15 and HCT116 GEF-resistant cells. Mechanically, TSPYL2 reduced the resistance to GEF and inhibited DNA damage repair via suppressing SIRT1-mediated FOXO3 deacetylation. TSPYL2 consistently inhibited tumor growth and decreased resistance to GEF in vivo . Conclusion: TSPYL2 reduced resistance to GEF and suppressed DNA damage through downregulating SIRT1-mediated FOXO3 deacetylation, indicating that TSPYL2 might be a novel therapeutic target in CRC.
Titel: |
TSPYL2 reduced gefitinib resistance and DNA damage repair via suppressing SIRT1-mediated FOXO3 deacetylation.
|
---|---|
Autor/in / Beteiligte Person: | Liu, Z ; Li, C ; Yu, C ; Chen, Z ; Zhao, C ; Ye, L |
Zeitschrift: | Future medicinal chemistry, Jg. 14 (2022-03-01), Heft 6, S. 407-419 |
Veröffentlichung: | London : Future Science, 2009-, 2022 |
Medientyp: | academicJournal |
ISSN: | 1756-8927 (electronic) |
DOI: | 10.4155/fmc-2021-0136 |
Schlagwort: |
|
Sonstiges: |
|